Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19

Affiliations

¹ Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA. joyner.michael@mayo.edu.
² Departments of Epidemiology and Biostatistics and Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing, MI, USA.
³ Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, USA.
⁵ Departments of Cardiovascular Medicine and Human Research Protection Program, Mayo Clinic, Rochester, MN, USA.
⁶ Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
⁷ Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Comment

Michael J Joyner et al. Nat Med. 2022 Jan.

. 2022 Jan;28(1):51-52.

doi: 10.1038/s41591-021-01638-6. Epub 2022 Jan 10.

¹ Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA. joyner.michael@mayo.edu.
² Departments of Epidemiology and Biostatistics and Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing, MI, USA.
³ Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, USA.
⁵ Departments of Cardiovascular Medicine and Human Research Protection Program, Mayo Clinic, Rochester, MN, USA.
⁶ Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
⁷ Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

No abstract available

Comment in

Reply to: Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19.
Bégin P, Callum J, Cook R, Jamula E, Liu Y, Finzi A; CONCOR-1 Study Group; Arnold DM. Bégin P, et al. Nat Med. 2022 Jan;28(1):53-58. doi: 10.1038/s41591-021-01639-5. Epub 2022 Jan 10. Nat Med. 2022. PMID: 35013612 No abstract available.

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC, Bruno KA, Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC, Baker SE, Shepherd JRA, van Helmond N, Verdun NC, Marks P, van Buskirk CM, Winters JL, Stubbs JR, Rea RF, Hodge DO, Herasevich V, Whelan ER, Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Paneth NS, Fairweather D, Wright RS, Casadevall A. Joyner MJ, et al. N Engl J Med. 2021 Mar 18;384(11):1015-1027. doi: 10.1056/NEJMoa2031893. Epub 2021 Jan 13. N Engl J Med. 2021. PMID: 33523609 Free PMC article.
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial.
Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, Zeller MP, Beaudoin-Bussières G, Amorim L, Bazin R, Loftsgard KC, Carl R, Chassé M, Cushing MM, Daneman N, Devine DV, Dumaresq J, Fergusson DA, Gabe C, Glesby MJ, Li N, Liu Y, McGeer A, Robitaille N, Sachais BS, Scales DC, Schwartz L, Shehata N, Turgeon AF, Wood H, Zarychanski R, Finzi A; CONCOR-1 Study Group; Arnold DM. Bégin P, et al. Nat Med. 2021 Nov;27(11):2012-2024. doi: 10.1038/s41591-021-01488-2. Epub 2021 Sep 9. Nat Med. 2021. PMID: 34504336 Free PMC article. Clinical Trial.

1. Bégin, P. et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat. Med. 27, 2012–2024 (2021). - DOI
1. Joyner, M. J. et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N. Engl. J. Med. 384, 1015–1027 (2021). - DOI
1. Anonymous. Updated evidence to support the emergency use of COVID-19 convalescent plasma – as of 9/23/2020. https://www.fda.gov/media/142386/download (2020).
1. Libster, R. et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N. Engl. J. Med. 384, 610–618 (2021). - DOI